A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia
Vulvar Neoplasm, Dysplasia Vulvar
About this trial
This is an interventional treatment trial for Vulvar Neoplasm
Eligibility Criteria
Inclusion Criteria: Written informed consent and HIPAA authorization for release of personal health information. Age ≥ 18 years at the time of consent Histological or cytological confirmation of VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS with a planned excisional procedure, with high suspicion by the enrolling investigator that gross surgical margins of ≥ 3 mm can be achieved without laser or other destructive procedures Surgery is expected to occur within 90 days from randomization Ability to read and understand the English and/or Spanish language As determined by the enrolling physician, ability and willingness of the subject to comply with study procedures for the entire length of the study No known pregnancy Exclusion Criteria: Excision is not possible due to anatomy (proximity to urethra/clitoris) Known immunodeficiency syndrome Immunosuppressant medications taken within the last 30 days (HIV, organ transplant recipient, chronic steroid use/immunosuppressant) History of pelvic region radiation therapy Active anticancer treatment
Sites / Locations
- Levine Cancer InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Frozen-Section Directed Excision Vulvectomy
Wide Local Excision Vulvectomy
The surgeon(s) will identify the lesion and make a 1 mm excision around the lesion site.
The surgeon(s) will visually identify the abnormal lesion. A Wide Local Excision with 5 mm margins will be made through the dermis per standard of care.